Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand TV, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Kaur G, Lau WCY, Li J, Li K, Liu Y, Lu Y, Man KKC, Matheny ME, Mathioudakis N, McLeggon JA, McLemore MF, Minty E, Morales DR, Nagy P, Ostropolets A, Pistillo A, Phan TP, Pratt N, Reyes C, Richter L, Ross JS, Ruan E, Seager SL, Simon KR, Viernes B, Yang J, Yin C, You SC, Zhou JJ, Ryan PB, Schuemie MJ, Krumholz HM, Hripcsak G, Suchard MA. Khera R, et al. Among authors: cook m. J Am Coll Cardiol. 2024 Sep 3;84(10):904-917. doi: 10.1016/j.jacc.2024.05.069. J Am Coll Cardiol. 2024. PMID: 39197980
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM.
Khera R, Dhingra LS, Aminorroaya A, Li K, Zhou JJ, Arshad F, Blacketer C, Bowring MG, Bu F, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Horban S, Lau WC, Li J, Liu Y, Lu Y, Man KK, Matheny ME, Mathioudakis N, McLemore MF, Minty E, Morales DR, Nagy P, Nishimura A, Ostropolets A, Pistillo A, Posada JD, Pratt N, Reyes C, Ross JS, Seager S, Shah N, Simon K, Wan EY, Yang J, Yin C, You SC, Schuemie MJ, Ryan PB, Hripcsak G, Krumholz H, Suchard MA. Khera R, et al. Among authors: cook m. BMJ Med. 2023 Oct 6;2(1):e000651. doi: 10.1136/bmjmed-2023-000651. eCollection 2023. BMJ Med. 2023. PMID: 37829182 Free PMC article.
Characteristics and Outcomes of Over a Million Patients with Inflammatory Bowel Disease in Seven Countries: Multinational Cohort Study and Open Data Resource.
Yanover C, Magen-Rimon R, Voss EA, Swerdel J, Sheahan A, Hall N, Park J, Park RW, Lee KJ, Shin SJ, Seo SI, Lee KJ, Falconer T, Haas L, Nagy P, Bowring MG, Cook M, Miller S, El-Hay T, Bivas-Benita M, Akiva P, Chowers Y, Weisshof R. Yanover C, et al. Among authors: cook m. Dig Dis Sci. 2024 Dec 26. doi: 10.1007/s10620-024-08787-x. Online ahead of print. Dig Dis Sci. 2024. PMID: 39724470
Butyrolactol A is a phospholipid flippase inhibitor that potentiates the bioactivity of caspofungin against resistant fungi.
Chen X, Duan HD, Hoy MJ, Koteva K, Spitzer M, Guitor AK, Puumala E, Hu G, Yiu B, Chou S, Bian Z, Guo ABY, Sun S, Robbins N, Cook MA, Truant R, MacNeil LT, Brown ED, Kronstad JW, Cowen LE, Heitman J, Li H, Wright GD. Chen X, et al. Among authors: cook ma. bioRxiv [Preprint]. 2025 Jan 6:2025.01.06.630955. doi: 10.1101/2025.01.06.630955. bioRxiv. 2025. PMID: 39829750 Free PMC article. Preprint.
2,811 results